Vestor Capital LLC Buys 5,212 Shares of Guardant Health, Inc. $GH

Vestor Capital LLC raised its position in Guardant Health, Inc. (NASDAQ:GH) by 27.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,381 shares of the company’s stock after acquiring an additional 5,212 shares during the quarter. Vestor Capital LLC’s holdings in Guardant Health were worth $4,349,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. ABS Investment Management LLC bought a new stake in shares of Guardant Health in the 2nd quarter worth $345,069,000. The Manufacturers Life Insurance Company purchased a new position in Guardant Health during the second quarter valued at $208,592,000. William Blair Investment Management LLC purchased a new position in Guardant Health during the second quarter valued at approximately $196,737,000. Allspring Global Investments Holdings LLC increased its stake in Guardant Health by 13.1% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 730,980 shares of the company’s stock worth $127,739,000 after buying an additional 84,471 shares in the last quarter. Finally, First Light Asset Management LLC raised its position in shares of Guardant Health by 57.5% during the second quarter. First Light Asset Management LLC now owns 441,586 shares of the company’s stock valued at $66,251,000 after buying an additional 161,287 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Price Performance

Shares of GH stock opened at $158.79 on Tuesday. Guardant Health, Inc. has a 1-year low of $74.55 and a 1-year high of $191.05. The company has a market cap of $21.31 billion, a price-to-earnings ratio of -43.15 and a beta of 1.67. The stock has a 50 day simple moving average of $169.26 and a 200-day simple moving average of $132.22.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.46. The business had revenue of $360.98 million during the quarter, compared to analysts’ expectations of $350.72 million. During the same quarter in the previous year, the company posted ($0.74) earnings per share. The company’s revenue was up 36.1% on a year-over-year basis. Analysts anticipate that Guardant Health, Inc. will post -3.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Guggenheim upped their price target on shares of Guardant Health from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Stephens raised their target price on shares of Guardant Health from $170.00 to $195.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a report on Thursday, October 15th. Royal Bank Of Canada lifted their price target on Guardant Health from $185.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Finally, Rothschild & Co Redburn began coverage on shares of Guardant Health in a research note on Tuesday, September 8th. They issued a “buy” rating and a $203.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Guardant Health has an average rating of “Moderate Buy” and a consensus target price of $191.00.

Insider Activity

In other news, insider Terilyn J. Monroe sold 46,300 shares of the company’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $165.12, for a total transaction of $7,645,056.00. Following the completion of the transaction, the insider directly owned 22,979 shares of the company’s stock, valued at approximately $3,794,292.48. This represents a 66.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Alex M. Azar II sold 826 shares of the company’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $175.00, for a total transaction of $144,550.00. Following the completion of the transaction, the director owned 825 shares of the company’s stock, valued at approximately $144,375. The trade was a 50.03% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 99,455 shares of company stock worth $16,752,081 over the last 90 days. Company insiders own 5.60% of the company’s stock.

Guardant Health Profile

Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring.

Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.